← Back to Search

Other

Lenalidomide for Multiple Myeloma

Phase 1
Waitlist Available
Led By Andrew J. Yee, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing a new combination of drugs to treat multiple myeloma.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum Tolerated Dose of ACE-011
Secondary outcome measures
Efficacy of ACE-011
Pharmacodynamic markers
Pharmacodynamic measures
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: ACE-011 (sotatercept)Experimental Treatment4 Interventions
ACE-011, Lenalidomide or pomalidomide, Dexamethasone
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ACE-011
2008
Completed Phase 2
~30
Pomalidomide
2011
Completed Phase 2
~1020
Lenalidomide
2005
Completed Phase 3
~1480
Dexamethasone
2007
Completed Phase 4
~2590

Find a Location

Who is running the clinical trial?

Multiple Myeloma Research ConsortiumNETWORK
20 Previous Clinical Trials
1,325 Total Patients Enrolled
19 Trials studying Multiple Myeloma
1,272 Patients Enrolled for Multiple Myeloma
Massachusetts General HospitalLead Sponsor
2,928 Previous Clinical Trials
13,198,322 Total Patients Enrolled
35 Trials studying Multiple Myeloma
2,635 Patients Enrolled for Multiple Myeloma
Andrew J. Yee, MDPrincipal InvestigatorMassachusetts General Hospital
1 Previous Clinical Trials
1 Trials studying Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Andrew Yee, MD 2012. "Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01562405.
All > Myeloma > Revlimid
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top